Kymera Therapeutics Announces Pricing of $250 Million Public Offering

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.8 million of shares of its common stock and, in lieu of common stock to […] The post Kymera Therapeutics Announces Pricing of $250 Million Public Off…

Edgewise details pivotal plans in Becker muscular dystrophy; Kymera’s $250M offering

Plus, news about Hummingbird, Percheron, Pfizer and I-Mab: Edgewise Therapeutics can’t get accelerated approval for muscle disease drug: The biotech said the FDA deemed its Phase 2 CANYON data "insufficient for ...

Edgewise Therapeutics Reports Positive Results on Sevasemten Program

Edgewise Therapeutics, which received early funding from CureDuchenne, has reported positive results in its sevasemten program for Becker and Duchenne muscular dystrophies. New open-label data in Becker from the MESA trial demonstrated sustained disease stabilization up to three years in participants, reinforcing prior clinical findings from the ARCH and CANYON trials. Edgewise also reported encouraging topline data from the Phase 2 trials in Du…